Weber is new CMO at Sensorion

pharmafile | October 28, 2026 | Appointment | |  Ear Nose & throat, Genetic disorders, Neurology, hearing loss 

Otologist and neurotologist Dr. Peter Weber has been appointed Chief Medical Officer of biotech Sensorion.

The company, which develops novel therapies to restore hearing and to treat and prevent hearing loss disorders said Weber will assume his new role from 2 Novemeber.

A Sensorian release noted Weber possessed deep expertise in rare genetic ear disorders and remains one of the few physicians to have led the clinical development of gene therapies for genetic hearing loss.

As Chief Medical Officer of Decibel Therapeutics, and later as Senior Medical Consultant to Regeneron, Weber guided several programmes for the inner ear. These included the otoferlin gene therapy that became the first FDA-approved gene therapy for genetic hearing loss. At Decibel, he also led a small molecule program to prevent hearing loss caused by cisplatin chemotherapy.